Loading
A phase 2 trial of clonoSEQ in Multiple myeloma, run by Washington University School of Medicine, now recruiting.
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance is a phase 2 interventional study registered as NCT06483100 by Washington University School of Medicine, with 65 participants planned, started 2024-12-20 and due to reach its primary completion in 2032-06-30. Interventions recorded: Elrantamab, clonoSEQ. Conditions recorded: Multiple Myeloma.
Linked to the drug clonoSEQ because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
Shares clonoSEQ and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares clonoSEQ and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.